Skip to main content
. Author manuscript; available in PMC: 2014 Jan 21.
Published in final edited form as: Vaccine. 2012 Dec 8;31(5):777–783. doi: 10.1016/j.vaccine.2012.11.076

Table 2.

IgG anti-capsular geometric mean concentrations (GMC) and proportion infants with anti-capsular antibody ≥0.35 μg/ml prior to receiving pneumococcal conjugate vaccine (PCV) in HIV-infected and HIV-uninfected infants.

Serotype HUUa n = 119 HEUb n = 124 p-Valuec ART+d n = 204–205 p-Valuee ART−f n = 104 p-Valueg
4 GMC 0.12 (0.09–0.15) 0.08 (0.07–0.1) 0.006 0.13 (0.11–0.15) 0.772 0.15 (0.12–0.18) 0.354
≥0.35 μg/ml 24; 20% (14–28) 7; 6% (3–11) 0.001 30; 15% (10–20) 0.094 18; 17% (11–26) 0.318
6B GMC 0.15 (0.12–0.19) 0.09 (0.07–0.11) 0.003 0.17 (0.14–0.21) 0.419 0.22 (0.16–0.29) 0.072
≥0.35 μg/ml 38; 32% (24–41) 17; 14% (9–21) 0.001 52; 26% (20–32) 0.227 29; 28% (20–37) 0.498
9V GMC 0.2 (0.15–0.26) 0.09 (0.07–0.11) <0.001 0.13 (0.11–0.16) 0.002 0.15 (0.11–0.2) 0.043
≥0.35 μg/ml 38; 32% (24–41) 16; 13% (8–20) 0.001 35; 17% (12–23) 0.007 20; 19% (13–28) 0.059
14 GMC 1 (0.77–1.29) 0.42 (0.33–0.53) <0.001 0.86 (0.71–1.05) 0.139 1.05 (0.78–1.42) 0.735
≥0.35 μg/ml 92; 77% (69–84) 76; 61% (52–69) 0.005 160; 78% (72–83) 0.806 80; 77% (68–84) 0.629
18C GMC 0.21 (0.16–0.26) 0.1 (0.08–0.12) <0.001 0.12 (0.1–0.13) <0.001 0.11 (0.09–0.14) <0.001
≥0.35 μg/ml 37; 31% (24–40) 17; 14% (9–21) <0.001 28; 14% (10–19) <0.001 16; 15% (10–24) 0.002
19F GMC 0.62 (0.49–0.8) 0.23 (0.18–0.28) <0.001 0.48 (0.4–0.57) 0.037 0.57 (0.43–0.75) 0.338
≥0.35 μg/ml 89; 75% (66–82) 42; 34% (26–43) <0.001 124; 60% (54–67) 0.008 64; 62% (52–70) 0.029
23F GMC 0.25 (0.2–0.31) 0.12 (0.1–0.15) <0.001 0.18 (0.16–0.21) 0.004 0.19 (0.16–0.24) 0.024
≥0.35 μg/ml 50; 42% (34–51) 22; 18% (12–25) <0.001 55; 27% (21–33) 0.001 32; 31% (23–40) 0.027
a

HUU: HIV non-infected children born to HIV non-infected mothers.

b

HEU: HIV-uninfected born to HIV-infected mothers.

c

p-Value comparing HEU to HUU infants.

d

ART+: HIV-infected children with CD4+ ≥ 25% at enrolment randomized to initiate ART immediately.

e

p-Value comparing ART+ to HUU infants.

f

ART−: HIV-infected children with CD4+ ≥ 25% at enrolment randomized to deferred anti-retroviral treatment (ART) arm.

g

p-Value comparing ART− to HUU children.